Elevated erythrocyte aggregation as a predisposing factor to aspirin resistance

• References

• 1 McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalenve, mechanisms, and clinical significance. Thromb Haemost 2002; 88: 711-5.
• 2 Resch KL, Ernst E, Matrai A. et al. Can rheologic variables be of prognostic relevance in arteriosclerotic disease?. Angiology 1991; 41: 963-70.
• 3 Stoltz JF, Donner M. Hemorheology: importance of erythrocyte aggregation. Clin Hemorheol 1987; 7: 15-23.
• 4 Demiroglu H. The importance of erythrocyte aggregation in blood rheology: considerations on the pathophysiology of thrombotic disorders. Blood 1997; 89: 4236
• 5 Demiroglu H, Barista I, Dundar S. The effects of age and menopause on erythrocyte aggregation. Thromb Haemost 1997; 77: 404
• 6 Demiroglu H, Yalcin S, Buyukasik Y. et al. Increased erythrocyte aggregation as an indicator for an aggressive clinical course in Behçet’s disease: a prospective study. Ann Rheum Dis 1998; 57: 694-6.
• 7 Demiroglu H, Gurlek A, Barista I. Enhanced erythrocyte aggregation in type 2 diabetes with late complications. Exp Clin Endocrinol Diabetes 1999; 107: 35-9.
• 8 Demiroglu H, Barista I, Dundar S. Erythrocyte aggregability in patients with coronary heart disease. Clin Hemorheol 1996; 16: 313-7.
• 9 Hayakawa M, Kuzuya F. Effects of ticlopidine on erythrocyte aggregation in thrombotic disorders. Angiology 1991; 42: 747-53.
• 10 Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent events (CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000; 24: 2033-41.